At the EAU Congress in London, experts presented data on the potential of Longidaza in restoring male fertility after COVID-19

New data on the role of Longidaza ® in the combination treatment of male infertility were presented at Europe’s largest annual urology event—the 41st Annual Congress of the European Association of Urology (EAU26) in London. The congress is the second-largest urology meeting worldwide and brought together more than 15,000 specialists from around the globe. Russian scientists highlighted how Longidaza ® , a product developed in Russia and used as part of combination treatment, may help improve the reproductive health of men suffering from post-COVID complications. Approximately 6% of men of reproductive age experience infertility, and in every second case this is an idiopathic form of the disease, the cause of which cannot be determined [ 1 ] . Infections, including previous COVID-19 infection, are among the factors proven to reduce fertility. In Russia, at least one in four men has experienced coronavirus infection [ 2 ] . According to new research by Russian scientists, a previous coronavirus infection may lead to structural tissue damage, reduced testosterone levels, and impaired fertility. The study authors conducted a comprehensive assessment of male reproductive function. They examined structural abnormalities using electron microscopy, analyzed hormonal status (testosterone levels), measured sperm counts and performed immunological assays, evaluated testicular hemodynamics, and carried out morphological tissue analysis. The study was the first to combine electron microscopy of sperm, assessment of testicular blood flow, and biopsy to establish evidence of fibrosis. "In-depth analysis revealed a significant impact of SARS-CoV-2: the virus directly affects testicular tissue, reduces hemodynamics, inducing sclerotic transformation and structural damage. Such findings remain evident even half a year after the patient has recovered. Persistent testosterone declines following infection represent a risk factor for hypogonadism and the associated decline in quality of life and overall health," reported scientists from Rostov State Medical University, who conducted the study.

The release as fetched from its publisher. petrovax.com ↗